Phase 1b (COSMIC-021) Trial of Cabozantinib Alone or in Combination With Atezolizumab in Patients With Solid Tumors Including Radioiodine (RAI)-Refractory Differentiated Thyroid Cancer (DTC)
Thyroid World Congress ePoster Library. Leboulleux S. 06/20/19; 272092; 204
Sophie Leboulleux
Sophie Leboulleux
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)

Background: VEGFR-targeted agents are standard of care for RAI-refractory DTC; however, treatment options are limited. Cabozantinib is an inhibitor of tyrosine kinases involved in tumor growth, including MET, VEGFR, and TAM kinases (Tyro3, AXL, MER). Cabozantinib promotes an immune-permissive tumor environment that may enhance response to immune checkpoint inhibitors, including anti-PD-L1 mAb atezolizumab. Cabozantinib has single-agent activity in patients with RAI-refractory DTC (Brose et al. ASCO 2018: Abstr 6088). We present the design of an ongoing phase 1b trial assessing cabozantinib+atezolizumab in patients with RAI-refractory DTC in the first-line setting.

Methods: This global, multicenter, phase 1b, open-label trial is evaluating safety, tolerability, preliminary efficacy, and pharmacokinetics of cabozantinib or cabozantinib + atezolizumab in solid tumors (NCT03170960). The study comprises a dose-escalation stage and an expansion stage. The dose-escalation stage (3+3 design) is completed. Cabozantinib 40 mg qd + atezolizumab 1200 mg q3w is recommended for expansion. One of the 18 combination cohorts is assessing cabozantinib+atezolizumab in 30 patients with DTC (follicular, papillary, and poorly differentiated histologies) who are RAI-refractory or ineligible, naïve to systemic therapy, and receiving thyroxine suppression therapy. Patients will continue treatment as long as they experience clinical benefit or until unacceptable toxicity per investigator. The primary endpoint is the objective response rate per RECIST 1.1. Secondary objectives include assessment of immune-related adverse events.

Results: This is an ongoing trial.

Discussion & Conclusions: This study will provide safety and preliminary efficacy data on cabozantinib+atezolizumab in solid tumors, including DTC.


Background: VEGFR-targeted agents are standard of care for RAI-refractory DTC; however, treatment options are limited. Cabozantinib is an inhibitor of tyrosine kinases involved in tumor growth, including MET, VEGFR, and TAM kinases (Tyro3, AXL, MER). Cabozantinib promotes an immune-permissive tumor environment that may enhance response to immune checkpoint inhibitors, including anti-PD-L1 mAb atezolizumab. Cabozantinib has single-agent activity in patients with RAI-refractory DTC (Brose et al. ASCO 2018: Abstr 6088). We present the design of an ongoing phase 1b trial assessing cabozantinib+atezolizumab in patients with RAI-refractory DTC in the first-line setting.

Methods: This global, multicenter, phase 1b, open-label trial is evaluating safety, tolerability, preliminary efficacy, and pharmacokinetics of cabozantinib or cabozantinib + atezolizumab in solid tumors (NCT03170960). The study comprises a dose-escalation stage and an expansion stage. The dose-escalation stage (3+3 design) is completed. Cabozantinib 40 mg qd + atezolizumab 1200 mg q3w is recommended for expansion. One of the 18 combination cohorts is assessing cabozantinib+atezolizumab in 30 patients with DTC (follicular, papillary, and poorly differentiated histologies) who are RAI-refractory or ineligible, naïve to systemic therapy, and receiving thyroxine suppression therapy. Patients will continue treatment as long as they experience clinical benefit or until unacceptable toxicity per investigator. The primary endpoint is the objective response rate per RECIST 1.1. Secondary objectives include assessment of immune-related adverse events.

Results: This is an ongoing trial.

Discussion & Conclusions: This study will provide safety and preliminary efficacy data on cabozantinib+atezolizumab in solid tumors, including DTC.


    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings